来那帕韦钠(Lenacapavir Sodium) - 药物靶点：HIV-1 capsid_在研适应症：HIV感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lenacapavir、来那帕韦、莱纳卡帕韦

+ [12]

靶点

HIV-1 capsid

作用方式

抑制剂

作用机制

HIV-1 capsid抑制剂(HIV-1衣壳蛋白抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

Gilead Sciences, Inc.

在研机构

Gilead Sciences, Inc.Gilead Biopharmaceutics Ireland UCGilead Sciences Ireland UC

+ [7]

非在研机构-

权益机构

Dr. Reddy's Laboratories Ltd.

EVA Pharma for Pharmaceuticals & Medical Appliances SAE

Gilead Sciences, Inc.

+ [5]

最高研发阶段批准上市

首次获批日期

欧盟 (2022-08-17),

HIV感染

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、孤儿药 (日本)、孤儿药 (韩国)、加速审评 (欧盟)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C39H32ClF10N7NaO5S2

InChIKeyQXFAXPSMLXKBJU-PZNXWHLTSA-N

CAS号2283356-12-5

关联

29

项与来那帕韦钠相关的临床试验

NCT07467018

/ Not yet recruitingN/AIIT

Mobile Vehicle-Based Delivery of Lenacapavir PrEP in Los Angeles County (MOVE-LA)

This project evaluates the implementation strategy of the delivery of lenacapavir pre-exposure prophylaxis (LEN PrEP) - a newly available long-acting, injectable medication for HIV prevention - via a mobile health van model for people who are unstably housed in Los Angeles County. People who are unhoused or are facing housing instability experience significant barriers to accessing HIV prevention care in traditional clinic settings. In 2022, approximately 13% of newly diagnosed HIV cases in Los Angeles County were experiencing homelessness, a 36% increase over the prior period. We will work with UCLA Health's Homeless Healthcare Collaborative (HHC), which operates mobile health vans staffed by clinicians, social workers, and community health workers, to bring LEN PrEP directly to community settings, such as shelters, encampments, community centers, and transitional housing facilities.
This study has three primary aims:
1. Characterize uptake of LEN PrEP among unstably housed people in Los Angeles County receiving health services via HHC's mobile program.
2. Evaluate how many study participants stay on LEN PrEP through 52 weeks.
3. Understand costs, acceptability, and sustainability of the mobile LEN PrEP delivery model.

开始日期2026-04-07

申办/合作机构

University of California, Los Angeles

NCT07473778

/ RecruitingN/A

Pioneering Research to Optimize Pre-exposure Prophylaxis (PrEP) Expansion With Lenacapavir (LEN)

The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP.
The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.

开始日期2026-03-17

申办/合作机构

Gilead Sciences, Inc.

NCT07497594

/ RecruitingN/A

Expanding PrEP Options Among Young MSM, Transgender and Non-binary Persons in Brazil: Incorporating Twice-yearly Lenacapavir for HIV Prevention - The ImPrEP LEN Brasil Study

The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP). The main questions it aims to answer are:
How many participants get HIV while using long-acting lenacapavir? How safe is long-acting lenacapavir in real-world health services? How many participants continue using their chosen prevention method over time? What factors help or make it harder for participants to stay on prevention? Researchers will compare two HIV prevention options to understand how they work in routine care: Long-acting lenacapavir, given as an injection under the skin every 6 months, Daily oral pre-exposure prophylaxis (PrEP), taken as a pill containing tenofovir disoproxil fumarate and emtricitabine, Participants will choose the prevention option they prefer after receiving counseling. This is not a randomized study. Researchers will follow participants for up to 2 years. Participants will: Receive either an injection every 6 months or take a daily pill, Visit the clinic regularly for HIV testing and health checkups, Receive testing and treatment for sexually transmitted infections, Answer questions about their health, medication use, and experiences, Receive prevention counseling and condoms. This study will help health services understand how to offer long-acting HIV prevention in Brazil and how to better support people who want to prevent HIV infection.

开始日期2026-02-03

申办/合作机构

Fundação Oswaldo Cruz

100 项与来那帕韦钠相关的临床结果

登录后查看更多信息

100 项与来那帕韦钠相关的转化医学

登录后查看更多信息

100 项与来那帕韦钠相关的专利（医药）

登录后查看更多信息

258

项与来那帕韦钠相关的文献（医药）

2026-03-17·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly

Article

作者: Renner, Nadine ; Wang, Yihang ; Waltmann, Curt ; Böcking, Till ; Gupta, Manish ; Jacques, David A. ; Voth, Gregory A. ; James, Leo C.

The HIV-1 capsid is a fullerene cone composed of hexameric and pentameric capsid proteins (CA) that packages the viral genome and mediates nuclear entry. Lenacapavir (LEN), a potent molecular long-acting inhibitor developed by Gilead, disrupts capsid morphogenesis by binding a phenylalanine–glycine (FG) pocket at the interface between adjacent CA subunits. Interestingly, cellular polyanion inositol hexakisphosphate (IP6) promotes conical capsid assembly by coordinating the central pore, which is allosterically coupled to the FG pocket. Because LEN and IP6 engage overlapping structural elements, they can compete to influence the capsid assembly pathway and outcomes. Using coarse-grained molecular simulations, we show that LEN accelerates hexamer formation while suppressing pentamer incorporation, yielding malformed, multilayered, and incomplete capsids. Simulations incorporating a ribonucleoprotein model further reveal that LEN-treated capsids often fail to encapsulate RNA, indicating impaired maturation. Our calculations confirm that LEN impairs the formation of high-curvature CA lattice regions necessary for closure, supporting a model of off-pathway assembly as a mechanism of viral inhibition. These findings define the core mechanism by which a small-molecule inhibitor disrupts the much larger-scale HIV-1 morphogenesis and underscore general principles for targeting self-assembling multi-protein complexes.

2026-03-01·ANNALS OF PHARMACOTHERAPY

Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis

Review

作者: Koren, David E. ; Sherman, Elizabeth M. ; Chahine, Elias B.

Objective::

To review the efficacy and safety of lenacapavir for the prevention of HIV-1 infection.

Data Sources::

Clinical trials and review articles were obtained through August 2025 using search terms lenacapavir, GS-CA1, GS-6207, capsid inhibitor, preexposure prophylaxis, and PrEP.

Study Selection and Data Extraction::

All relevant articles, trials, and abstracts in the English language were included.

Data Synthesis::

Lenacapavir uses a novel mechanism for HIV prevention administered through subcutaneous injection. In a counterfactual design, lenacapavir arms demonstrated superior efficacy for prevention against a background HIV incidence rate across a variety of populations and gender identities. Adverse events commonly reported include injection-site reactions, which may include nodules, pain, or swelling at the injection site.

Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs::

The extended dosing frequency of lenacapavir may uniquely serve patients at risk of HIV acquisition who are unable or unwilling to take oral prevention medications. The mechanism of action for lenacapavir is not duplicative of other medications used in first-line antiretroviral regimens and thus may not risk resistance to regularly used classes if resistance occurs. Lenacapavir is a moderate cytochrome P450 inhibitor and thus may have interactions with other medications; however, neither renal nor hepatic dose adjustments are required.

Conclusions::

Lenacapavir provides a long-acting injectable option for people seeking a pharmacologic prevention agent against HIV-1. Despite injection-site reactions being relatively common, these did not present a barrier to treatment continuation among trial participants.

2026-03-01·INTERNATIONAL JOURNAL OF STD & AIDS

High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV

Article

作者: Miller, Theodore R. ; Sison, Raymund ; Gruta, Cristina ; Fierer, Daniel S.

A 19 year old man was diagnosed newly acquired HIV and prescribed bictegravir/emtricitabine/tenofovir alafenamide at his initial visit for HIV care. The genotype results from that initial visit returned two weeks later, showing high-level multi-class transmitted drug resistance, including multiple resistance-associated mutations (RAM) in the integrase gene. Although he had an initial substantial decline in viremia in the first 4 weeks, it was felt that the risk of subsequent failure was too high, and his antiretroviral treatment (ART) regimen was therefore changed to daily dolutegravir and darunavir/cobicistat/emtricitabine/tenofovir alafenamide, plus injected lenacapavir. He had durable virologic suppression on this new regimen for 12 months as of his last follow-up. This case of high-level multi-class transmitted drug resistance, in the context of rapid emergence of resistance to dolutegravir where it has been used as part of a salvage regimen, suggests that assessing for RAM in the integrase gene should be added to the currently recommended resistance testing for all patients with newly acquired HIV prior to initiating ART.

831

项与来那帕韦钠相关的新闻（医药）

2026-04-07

·摩熵医药

填补国产空白！艾迪药业长效HIV预防1类新药获批临床

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 4月7日，艾迪药业宣布自主研发的1类新药ACC085注射液正式获得国家药品监督管理局（NMPA）临床试验批准，拟用于有HIV-1感染风险的成人和体重至少35kg青少年的暴露前预防（PrEP）。这也是国内首个自主研发并进入临床试验阶段的长效 HIV 衣壳抑制剂类 PrEP 药物。ACC085的获批标志着国产长效HIV预防药物迈出关键一步，打破了国外巨头在该领域的长期垄断。截图来源：企业公告 01 攻克耐药难题国产长效PrEP实现零的突破 ACC085是艾迪药业基于十余年抗艾研发积淀推出的重磅新品，属于新一代HIV-1衣壳功能抑制剂。与传统药物不同，它通过精准结合衣壳蛋白亚基界面，靶向干扰病毒核摄取、组装释放及衣壳核形成等多个生命周期关键环节，从源头抑制HIV-1复制。截图来源：全球药物研发数据库（更多点击小程序查看）临床前研究数据显示，ACC085不仅对HIV-1实验株、临床分离株表现出强效抗病毒活性，更能有效覆盖多种耐药株，且在动物模型中展现出优异的预防保护效力。更为关键的是，其明确的药代动力学特征有力支持了该分子的长效开发潜力，有望为患者提供给药频率更低、依从性更高的预防选择。目前，全球范围内仅吉利德的来那帕韦获批长效PrEP适应症，国内市场尚无自主研发的长效预防药物上市。ACC085作为国产首个进入临床阶段的同类药物，将直接填补这一空白，为国内HIV防控提供自主可控的创新工具。 02 业绩高速增长艾迪药业全场景布局成型 ACC085获批临床，不仅是技术上的突破，更是艾迪药业商业化能力的强力背书。据2025年年报数据显示，公司营收同比增速高达72.13%，其中抗HIV创新药收入增长89.72%，显示出强劲的市场爆发力。此前，艾迪药业已成功构建起覆盖HIV感染者“初治-经治”全流程的需求闭环，推出了艾诺米替、艾诺韦林等多款1类新药。随着ACC085进入临床阶段，公司管线实现了从“治疗”到“预防”的战略延伸，完成了HIV领域“筛查-预防-治疗-管理”的全场景布局。结语从救治已感染者到守护高危易感人群，艾迪药业正以持续的研发投入应对全球防艾挑战。ACC085临床试验的正式启动，不仅代表了国产创新药在HIV长效预防领域的硬实力，更为终结艾滋病流行注入了“中国动能”。期待这款极具潜力的创新药物能早日获批上市，惠及更广泛的人群，助力构建无“艾”未来。 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作报告定制数据库咨询数据定制媒体合作点击阅读原文，申请摩熵医药企业版免费试用！

2026-04-07

·氨基观察

赛诺菲自免双抗两项II期研究成功；吉利德长效HIV预防新药拟纳入优先审评

氨基观察-创新药组原创出品作者 | 黄恺赛诺菲自免双抗研发再进一步。 4月7日，赛诺菲宣布，TSLP/IL-13双抗lunsekimig在两种慢性呼吸系统疾病中进行的II期研究均达到了主要终点和关键次要终点。在两项研究中，lunsekimig耐受性良好，安全性特征可接受。吉利德长效HIV预防新药拟纳入优先审评。 4月7日，据CDE官网，吉利德来那帕韦钠片和来那帕韦钠注射液新适应症拟纳入优先审评，适用于与安全的性行为相结合，对于感染风险较高的成人和青少年（体重至少在 35kg 以上）进行暴露前预防，以降低通过性行为感染 HIV-1的风险。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 资本信息 1）聚芯医疗完成近2亿元C轮融资 4月7日，脑医学科技平台聚芯医疗科技完成近2亿元人民币C轮融资。 / 02 / 医药动态 1）吉利德长效HIV预防新药拟纳入优先审评 4月7日，据CDE官网，吉利德来那帕韦钠片和来那帕韦钠注射液新适应症拟纳入优先审评，适用于与安全的性行为相结合，对于感染风险较高的成人和青少年（体重至少在 35kg 以上）进行暴露前预防，以降低通过性行为感染 HIV-1的风险。 2）全球首创BCL6 PROTAC获批临床日前，据CDE 官网，BMS全球首创BCL6 PROTAC药物BMS-986458 片获批临床，用于复发/难治非霍奇金淋巴瘤。 3）抗创联生物SYH2069注射液获临床许可 4月7日，据CDE官网，抗创联生物SYH2069注射液获临床许可，作为饮食和运动的辅助药物，用于改善患有2型糖尿病（T2DM）的成年人的血糖控制。 / 03 / 海外药闻 1）赛诺菲TSLP/IL-13双抗两项II期研究成功 4月7日，赛诺菲宣布，TSLP/IL-13双抗lunsekimig在两种慢性呼吸系统疾病中进行的II期研究均达到了主要终点和关键次要终点。在两项研究中，lunsekimig耐受性良好，安全性特征可接受。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

2026-04-07

·药圈头条

一年两次，吉利德长效HIV预防新药拟纳入优先审评

今日（4 月7日），CDE 官网显示，吉利德的来那帕韦钠片和来那帕韦钠注射液新适应症拟纳入优先审评，适用于与安全的性行为相结合，对于感染风险较高的成人和青少年（体重至少在35kg以上）进行暴露前预防，以降低通过性行为感染HIV-1的风险。其中来那帕韦钠片为来那帕韦钠注射液的注射前口服导入用药，并用于在两次来那帕韦钠注射给药之间需要时进行口服桥接。据公开资料显示，来那帕韦钠是一款全球首创的HIV-1衣壳抑制剂，因为采用缓释技术，来那帕韦钠注射液制剂可从注射部位缓慢释放，并维持有效浓度达 26 周，实现每半年一次的皮下给药。来那帕韦钠最早于2022年8月在欧盟获批上市，用于联合其他抗逆转录病毒药物治疗多重耐药HIV-1感染的成人患者。在治疗初期，患者可以通过口服片剂来启动治疗，随后每半年仅需皮下注射一次注射剂即可维持稳定的病毒抑制效果，后面该适应症陆续在美国、日本、加拿大、中国获批。 2025年6月，FDA 正式批准来那帕韦钠新适应症上市申请，用于体重35kg以上青少年与成人的HIV暴露前预防，成为全球首款只需一年两次注射的HIV预防措施，也是全球首个覆盖治疗与预防全周期的长效HIV药。欢迎加入交流群

100 项与来那帕韦钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15673

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	欧盟	Gilead Biopharmaceutics Ireland UC	2022-08-17
HIV感染	冰岛	Gilead Biopharmaceutics Ireland UC	2022-08-17
HIV感染	列支敦士登	Gilead Biopharmaceutics Ireland UC	2022-08-17
HIV感染	挪威	Gilead Biopharmaceutics Ireland UC	2022-08-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05729568 (Pubmed \| Lancet Microbe)	临床2期	HIV感染	80	Lenacapavir+Teropavimab+Zinlirvimab	餘繭鹽選鑰齋構蓋餘顧(糧廠構顧積遞觸廠積淵) = 構觸遞壓衊顧製觸糧膚齋範夢蓋廠繭鹽襯淵築 (廠襯窪鹹壓淵醖蓋艱壓 )	积极	2026-02-01
				SBR	築觸積壓鑰構鬱憲醖簾(餘夢繭鬱獵鏇鬱膚鹹築) = 獵蓋繭鑰構鏇遞構築鹹獵製鏇鏇壓襯顧窪積築 (壓艱築簾網鹹鹹夢鹽簾, 0.0 ~ 12.8) 更多
NCT05052996 (Pubmed \| Ann Intern Med)	临床2期	HIV感染	104	Islatravir + Lenacapavir	簾網積餘醖餘蓋築餘選(願簾廠範艱壓蓋淵鹹壓) = 獵壓壓憲壓窪艱鹽衊觸積積獵艱餘糧網鏇衊遞 (築簾範衊淵膚鑰製願觸 ) 更多	积极	2025-12-23
				Bictegravir, Emtricitabine, Tenofovir Alafenamide	鹹鹽範製鹹壓糧鬱願選(蓋鏇繭憲網鑰遞壓願窪) = 鹹衊醖繭餘窪繭醖顧網窪蓋製觸築網蓋選夢鬱 (壓鬱顧壓顧齋鬱網餘積 ) 更多
NCT04994509 \| NCT04925752 (PURPOSE 2, NEWS) 人工标引	临床3期	HIV感染	-	lenacapavir (每年两次)	鏇鏇壓糧獵築壓觸襯範(餘蓋遞獵醖築觸廠鑰憲) = 孕妇与非孕妇安全性相似，按妊娠期或产后状态预测的Yeztugo 暴露无临床显著差异，母乳喂养婴儿暴露量也极小。衊憲醖繭淵繭網製獵衊 (遞鬱簾願醖衊齋蓋衊鑰 ) 更多	积极	2025-07-16
NCT05729568 (CTgov)	临床2期	HIV感染	83	Antiretroviral Therapy	膚醖膚夢範蓋淵鹹廠齋 = 鑰齋醖構積製鹹窪構窪鹽鑰願鹹壓築獵壓製築 (簾窪繭襯夢製憲鹽糧繭, 遞夢襯壓積淵選蓋範築 ~ 廠艱糧範衊獵憲網餘醖) 更多	-	2025-07-15
NCT04994509 \| NCT04925752 (PURPOSE 2, FDA_CDER) 人工标引	临床3期	HIV感染	-	YEZTUGO (PURPOSE 1)	製壓襯膚艱鹹鬱築鏇鹹(蓋範餘選壓鹽壓淵觸觸) = 餘獵範壓齋鏇夢獵積窪積廠願窪膚鬱遞餘餘鏇 (淵願壓獵積觸憲廠衊獵 )	积极	2025-06-18
				TRUVADA (PURPOSE 1)	製壓襯膚艱鹹鬱築鏇鹹(蓋範餘選壓鹽壓淵觸觸) = 鏇選遞膚窪鏇壓繭簾積積廠願窪膚鬱遞餘餘鏇 (淵願壓獵積觸憲廠衊獵 )
NCT04150068 (Phase 2/3 Trial, Pubmed \| Clin Infect Dis)	临床2/3期	HIV感染 multidrug-resistant HIV-1	72	Lenacapavir + OBR	醖醖淵夢餘觸遞網遞鏇(選艱遞醖窪衊獵願鹽構) = There were no Grade 4 or serious treatment-related adverse events 鬱鑰願遞積選獵壓鏇蓋 (窪壓衊製獵蓋獵簾憲選 ) 更多	积极	2025-03-17
PipelineReview \| Pubmed 人工标引	临床1期	HIV感染	40	ventrogluteal intramuscular injection lenacapavir with 5% w/w ethanollenacapavir with 5% w/w ethanol	鏇積築鹽糧窪餘積顧蓋(築繭製鬱醖餘廠願築願) = 鏇鬱淵夢淵構憲繭積餘壓鏇餘獵鑰顧鏇醖願醖 (艱鏇範鏇餘淵簾鏇觸餘, 56.1 ~ 112.0) 更多	积极	2025-03-12
				ventrogluteal intramuscular injection lenacapavir with 10% w/w ethanollenacapavir with 10% w/w ethanol	鏇積築鹽糧窪餘積顧蓋(築繭製鬱醖餘廠願築願) = 廠衊範簾餘壓築襯鹽膚壓鏇餘獵鑰顧鏇醖願醖 (艱鏇範鏇餘淵簾鏇觸餘, 55.3 ~ 105.5) 更多
NCT04811040 (CTgov)	临床1期	HIV感染	32	LEN+Zinlirvimab+Teropavimab (Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg)	簾憲膚淵餘蓋網鬱選獵 = 醖艱選鹹廠願夢觸夢構膚膚糧餘淵鹽壓衊繭鬱 (膚鏇製鹽鬱齋選顧範襯, 製憲窪鹽願齋簾觸廠蓋 ~ 網網膚膚齋憲淵淵廠願) 更多	-	2025-01-27
				LEN+Zinlirvimab+Teropavimab (Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg)	簾憲膚淵餘蓋網鬱選獵 = 顧獵夢夢襯遞醖製鑰膚膚膚糧餘淵鹽壓衊繭鬱 (膚鏇製鹽鬱齋選顧範襯, 淵艱鑰簾壓範鏇遞築製 ~ 窪網鬱鬱鹹壓淵製蓋淵) 更多
NCT05052996 (CTgov)	临床2期	HIV感染	142	LEN+ISL (Cohort 1- Group 1 (ISL+LEN))	衊顧繭遞遞製願簾壓繭(鏇願獵窪鬱夢糧遞簾夢) = 淵鑰網繭繭繭窪衊夢齋衊膚艱遞顧顧鑰醖繭淵 (淵網夢廠窪鬱願鏇襯遞, 265.0) 更多	-	2025-01-14
				LEN+ISL (Cohort 1- Group 2 (B/F/TAF to ISL+LEN))	衊顧繭遞遞製願簾壓繭(鏇願獵窪鬱夢糧遞簾夢) = 顧鏇範構簾襯鹹衊廠觸衊膚艱遞顧顧鑰醖繭淵 (淵網夢廠窪鬱願鏇襯遞, 304.8) 更多
NCT04925752 (PURPOSE 2, Pubmed \| N Engl J Med) 人工标引	临床3期	HIV感染	3,265	Lenacapavir	廠餘獵製廠醖積範膚構(觸觸膚淵壓觸廠廠醖網) = 鏇襯鹹願積鹽獵鏇襯簾艱蓋齋夢選顧壓築鏇糧 (簾憲觸觸積選襯觸願窪, 0.01 ~ 0.37) 更多	积极	2024-11-27
				Emtricitabine-tenofovir disoproxil fumarate (F/TDF)	廠餘獵製廠醖積範膚構(觸觸膚淵壓觸廠廠醖網) = 鹹夢網範觸遞範觸遞網艱蓋齋夢選顧壓築鏇糧 (簾憲觸觸積選襯觸願窪, 0.43 ~ 1.77) 更多